The cost-effectiveness of testing on actionable target to guide NSCLC therapy has been examined on gene testing of anaplastic lymphoma kinase for crizotinib therapy in China, and T70M resistance for osimertinib therapy in Canada [25, 26]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.